

Cleveland BioLabs, Inc.

- Located in Buffalo, NY
- Clinical-stage biotechnology company with a focus on oncology and orphan drug development located on the Buffalo Niagara Medical Campus
- Formed in 2003 by Andrei V. **Gudkov**, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
- Pursuing the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients
- Publicly funded corporation (Nasdaq:CBLI) and has nine product candidates in their pipeline, most notably Entolimod (CBLB502), which is currently in clinical studies
- These candidates are being developed directly by Cleveland BioLabs and their majority-owned subsidiaries, Incuron, L.L.C. and Panacela Labs, Inc.
- For more information, visit www.cbiolabs.com.

Incuron, L.L.C.

- Located in Buffalo, NY
- Headquartered in Russia
- Drug development company formed in 2009 by Andrei V. Gudkov, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
- Joint venture formed between Cleveland BioLabs and BioProcess Capital Ventures (a Russian investment company) and majority owned by Cleveland BioLabs
- Actively developing compounds that fight cancer, specifically CBL0137 and CBL0102. CBL0137 is in clinical studies and CBL0102 has been granted orphan drug status
- For more information, visit www.incuron.com/en.

Panacela Labs, Inc.

- Headquartered in Buffalo, NY
- Drug development company formed in 2011 by Andrei V. **Gudkov**, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
- Joint venture founded by Cleveland BioLabs and Rusnano (a Russian investment company) in collaboration with Roswell Park Comprehensive Cancer Center, Children's Cancer Institute of Australia and Cleveland Clinic Foundation
- Focused on developing five product candidates from the laboratory of Dr. **Gudkov**:
 - **Revercom** – Chemotherapy sensitizer
 - **Mobilan** – Adenovirus-based cancer immunotherapy
 - **Arkil** – Inhibitor of Androgen receptor targeting prostate cancer
 - **Antimycon** – Inhibitor of MYC oncogene
 - **Xenomycins** – Anti-bacterial and anti-fungal family of compounds
- For more information, visit www.panacelalabs.com.

Oncotartis, Inc.

- Headquartered in Buffalo, NY
- Drug development company formed in 2011 by Andrei V. **Gudkov**, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
- Privately funded and has received funding from BioProcess (a Russian investment company)
- Actively developing compounds that fight cancer
- For more information, visit www.tartiscorp.com.

Everon Biosciences

- Headquartered in Buffalo, NY
- Drug development company formed in 2011 by Andrei V. **Gudkov**, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
- Privately funded
- Actively developing compounds that fight the aging process and age related diseases
- For more information, visit www.tartiscorp.com.